# IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

> **NCT06974812** · PHASE1,PHASE2 · RECRUITING · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 250 (estimated)

## Conditions studied

- Unresectable Locally Advanced or Metastatic Solid Tumors

## Interventions

- **DRUG:** IBI3014
- **DRUG:** IBI3014
- **DRUG:** IBI3014
- **DRUG:** IBI3014
- **DRUG:** IBI3014
- **DRUG:** IBI3014
- **DRUG:** IBI3014
- **DRUG:** IBI3014

## Key facts

- **NCT ID:** NCT06974812
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-18
- **Primary completion:** 2026-06-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2026-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06974812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06974812, "IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06974812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*